Benzinga · Nov 2, 2026
TD Cowen Maintains Buy on Fortrea Holdings, Raises Price Target to $26
TD Cowen analyst Charles Rhyee maintains Fortrea Holdings (NASDAQ:FTRE) with a Buy and raises the price target from $23 to $26.
FT
NASDAQ · FTRE
Fortrea Holdings Inc.
Healthcare · Biotechnology
$21.96
Up+$1.50 (+7.33%)
Updated Nov 8, 2026, 11:10 AM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.4B
- P/E ratio
- -1.4
- Dividend yield
- 0.00%
- 52-week range
- $8.55 – $26.16
- Volume
- 1.94M
- Avg. volume
- 1.34M
Price performance · FTRE
FTRE price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
FTRE closed at $21.96 after 20 trading sessions, up 4.57% for the selected period.
- Last close
- $21.96
- Period change
- +4.57%
- Period low
- $20.02
- Period high
- $25.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $20.46 | $22.12 | $20.14 | $21.96 | 1.94M |
| Nov 5, 2026 | $20.53 | $20.80 | $19.89 | $20.46 | 2.4M |
| Nov 4, 2026 | $21.42 | $21.84 | $20.15 | $20.83 | 1.44M |
| Nov 3, 2026 | $19.93 | $21.33 | $19.66 | $20.95 | 1.58M |
| Nov 2, 2026 | $21.41 | $21.56 | $19.745 | $20.02 | 1.75M |
| Oct 30, 2026 | $23.295 | $23.51 | $20.70 | $21.29 | 2.87M |
| Oct 29, 2026 | $23.63 | $23.79 | $22.405 | $23.135 | 4.95M |
| Oct 28, 2026 | $24.36 | $26.16 | $24.30 | $25.88 | 3.59M |
| Oct 27, 2026 | $23.725 | $24.52 | $23.50 | $24.43 | 1.97M |
| Oct 26, 2026 | $23.63 | $24.14 | $23.63 | $23.83 | 1.04M |
| Oct 23, 2026 | $23.92 | $24.048 | $23.4241 | $23.63 | 1M |
| Oct 22, 2026 | $23.95 | $24.835 | $23.24 | $23.92 | 1.99M |
| Oct 21, 2026 | $22.45 | $24.37 | $22.302 | $24.06 | 2.48M |
| Oct 20, 2026 | $22.55 | $23.55 | $22.305 | $22.78 | 2.38M |
| Oct 19, 2026 | $22.49 | $23.04 | $22.38 | $22.42 | 1.65M |
| Oct 16, 2026 | $23.04 | $23.135 | $21.86 | $22.49 | 1.9M |
| Oct 15, 2026 | $21.93 | $23.07 | $21.63 | $22.745 | 2.91M |
| Oct 14, 2026 | $20.45 | $22.15 | $20.25 | $21.34 | 2.94M |
| Oct 13, 2026 | $21.11 | $21.215 | $20.60 | $20.92 | 767.67K |
| Oct 12, 2026 | $20.84 | $21.3118 | $20.675 | $21.00 | 1.24M |
Latest FTRE news
The latest Smart Investors Daily articles mentioning FTRE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
FTRE research
Overview
Company profile and research snapshot.
Company profile
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 2, 2026 | TD Cowen | Buy | — |
| Oct 30, 2026 | Citigroup | Buy | — |
| Oct 30, 2026 | Truist Securities | Buy | — |
| Oct 30, 2026 | Barclays | Overweight | — |
| Oct 30, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 1, 2026
FTRE Q3 deep dive: margin gains, backlog reset, and early-phase expansion shape outlook
Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q3 2026 results beating Wall Street’s revenue expectations, but sales fell by 1.4% year on year to $691.5 million. The company’s full-year revenue guidance of $2.68 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $0.28 per share was 28.9% above analysts’ consensus estimates.
Yahoo · Oct 31, 2026
Earnings Beat Could Reset The Case For Fortrea Stock
Fortrea Holdings reported Q3 2026 revenue of US$691.5 million and returned to a modest profit, while also narrowing and raising full year 2026 revenue guidance to a range of US$2.665 billion to US$2.69 billion. The acquisition of Worldwide Clinical Trials' Early Phase Services business expands Fortrea Holdings' clinical pharmacology footprint, which directly supports its efforts to improve growth and margins. This analysis now considers how Fortrea Holdings' raised 2026 revenue outlook could...
Yahoo · Oct 31, 2026
Fortrea Holdings (FTRE) Stock Sees Modest Fair Value Lift As Margin Views Improve
Fortrea Holdings now carries a modestly higher fair value estimate, moving from US$20.55 to US$21.71 per share, as analysts refresh their models. Behind this change, recent commentary shows bulls and bears debating how current margins, revenue visibility, and execution risks line up with where the stock trades today. As you read on, you will see how this updated pricing framework fits into the evolving analyst narrative and what it could mean for how you track Fortrea from here. Stay updated...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
